In the hypoxic tumour environment, vascular endothelial growth factor (VEGF) is released by the hypoxia and acts on endothelial cells to promote angiogenesis; consequently antibody (bevacizumab) to VEGF has been used clinically to try to suppress blood vessel formation, but patients become resistant to this treatment. The gene discussed is VEGFA; the disease is neoplasm.